Trial Profile
A retrospective study to compare the efficacy of lamivudine vs entecavir for the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2016
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 06 Feb 2016 New trial record
- 11 Jan 2016 Results published in the Bone Marrow Transplantation